H5O0 Stock Chart & Stats
€0.02
>-€0.01(-4.35%)
At close: 4:00 PM EDT
€0.02
>-€0.01(-4.35%)
Day’s Range― - ―
52-Week Range€0.01 - €0.07
Previous CloseN/A
Volume0.00
Average Volume (3M)242.00
Market Cap
€2.84M
Enterprise Value€10.41M
Total Cash (Recent Filing)€1.53M
Total Debt (Recent Filing)€8.91M
Price to Earnings (P/E)―
Beta-2.22
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding116,609,580
10 Day Avg. Volume251
30 Day Avg. Volume242
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-0.54
Price to Sales (P/S)7.94
P/FCF Ratio-0.50
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Niche Therapeutic FocusArgent’s focus on cannabinoid-based therapeutics and specialty pharmaceuticals is a durable strategic niche. Targeting regulated specialty channels can create differentiated, higher-margin product opportunities and regulatory know‑how that competitors may find hard to replicate, supporting long‑term commercial potential if execution and approvals progress.
Improved Product Gross MarginsA material gross margin improvement in 2025 indicates stronger unit economics at the product level. If sustained, higher gross margins provide structural leverage to operating profitability as revenues scale, reducing the revenue threshold needed to reach break‑even and improving the company’s long‑term margin sustainability.
Lean Operating FootprintA very small headcount implies a lean fixed‑cost base and operational agility, which can meaningfully extend runway versus larger organizations. For an early‑stage pharma specialist, low overhead helps conserve cash while pursuing approvals or partnerships, making the business model more resilient during prolonged development cycles.
Bears Say
Negative Equity / Weak Balance SheetNegative shareholders’ equity across multiple years is a major structural weakness that reduces financial flexibility. It constrains access to non‑dilutive financing, increases creditor sensitivity, and raises execution risk for R&D and commercialization initiatives, making sustained investment and scaling more difficult without material recapitalization.
Persistent Cash BurnOperating cash flow reported as zero and repeated large negative free cash flows imply ongoing dependence on external funding. Persistent cash burn is a durable risk: it pressures liquidity, forces dilutive financing or asset sales, and can derail long‑term programs if capital markets or partner funding are unavailable when needed.
Sustained Revenue Contraction And LossesSharp multi‑year revenue decline combined with large operating and net losses indicates structural commercialization or demand challenges. Without a credible path to revive sustainable top‑line growth, the company’s improved gross margins are unlikely to cover fixed R&D and SG&A, keeping profitability and cash generation out of reach.
Argent Biopharma News
H5O0 FAQ
What was Argent Biopharma’s price range in the past 12 months?
Argent Biopharma lowest stock price was €0.01 and its highest was €0.07 in the past 12 months.
What is Argent Biopharma’s market cap?
Argent Biopharma’s market cap is €2.84M.
When is Argent Biopharma’s upcoming earnings report date?
Argent Biopharma’s upcoming earnings report date is Aug 28, 2026 which is in 23 days.
How were Argent Biopharma’s earnings last quarter?
Argent Biopharma released its earnings results on Feb 27, 2026. The company reported -€0.023 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.023.
Is Argent Biopharma overvalued?
According to Wall Street analysts Argent Biopharma’s price is currently Overvalued.
Does Argent Biopharma pay dividends?
Argent Biopharma does not currently pay dividends.
What is Argent Biopharma’s EPS estimate?
Argent Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Argent Biopharma have?
Argent Biopharma has 116,609,580 shares outstanding.
What happened to Argent Biopharma’s price movement after its last earnings report?
Argent Biopharma reported an EPS of -€0.023 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.
Which hedge fund is a major shareholder of Argent Biopharma?
Currently, no hedge funds are holding shares in DE:H5O0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argent Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
DE:H5O0 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-30.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-29.21%
Trailing 12-Months
Company Description
Argent Biopharma
Argent BioPharma Limited, an Australian-headquartered biopharmaceutical firm founded in 2014, operates as a clinical-stage entity focused on developing innovative nano-engineered therapeutics. The company's core mission involves crafting treatments designed to re-establish a healthy balance between the nervous and immune systems, with its reach extending internationally to locations including Malta and Slovenia. Its diverse pipeline of product candidates is progressing through various clinical phases. CimetrA, a leading contender, is currently in Phase III trials targeting acute lung injury and Acute Respiratory Distress Syndrome (ARDS). For refractory epilepsy, CannEpil is undergoing Phase I clinical evaluation. Additionally, CogniCann is advancing through Phase IIA trials, aiming to offer symptomatic relief for Dementia and Alzheimer's disease. Beyond these clinical programs, Argent BioPharma is actively involved in the preclinical development of Irnican for Glioblastoma Multiforme and dedicates research and development efforts to wound treatment. The company has also forged a strategic partnership with SINTEF to enhance antimicrobial solutions for chronic wounds and explore potential applications in oncologic wound care. Previously known as MGC Pharmaceuticals Limited, the company officially rebranded to Argent BioPharma Limited.
Technical Analysis
Elixinol Wellness
―
Cann Group
―
Little Green Pharma Ltd.
―
Althea Group Holdings Ltd.
―
Cronos Australia Ltd.
―